Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Effect of Nitazoxanide on the Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Mohamed Abuelazm, Ahmed Ghanem, Ahmed K. Awad, et al.
Clinical Drug Investigation (2022) Vol. 42, Iss. 12, pp. 1031-1047
Open Access | Times Cited: 9

Showing 9 citing articles:

Anthelmintic nitazoxanide protects against experimental pulmonary fibrosis
Xuyang Chen, Yan‐Chao Dong, Yuanyuan Yu, et al.
British Journal of Pharmacology (2023) Vol. 180, Iss. 23, pp. 3008-3023
Closed Access | Times Cited: 10
The African Kelleni’s roadmap using nitazoxanide and broad-spectrum antimicrobials to abort returning to COVID-19 square one
Mina Kelleni
Inflammopharmacology (2023) Vol. 31, Iss. 6, pp. 3335-3338
Open Access | Times Cited: 9
The clinical antiprotozoal drug nitazoxanide and its metabolite tizoxanide extend Caenorhabditis elegans lifespan and healthspan
Wenfeng Li, Shuming Chen, Jing Lang, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 7, pp. 3266-3280
Open Access | Times Cited: 2
Effect of methotrexate hold on COVID-19 vaccine response in the patients with autoimmune inflammatory disorders: a systematic review and meta-analysis
Muhammad Imran, Shujaat Ali, Ahmed A. Ibrahim, et al.
Clinical Rheumatology (2024) Vol. 43, Iss. 7, pp. 2203-2214
Closed Access | Times Cited: 2
One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial
Nikolaus Jilg, Kara W. Chew, Mark J. Giganti, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 7, pp. 941-949
Closed Access | Times Cited: 7
Safety and Efficacy of Camostat Mesylate for Covid-19: a systematic review and Meta-analysis of Randomized controlled trials
Ubaid Khan, Muhammad Mubariz, Yehya Khlidj, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Nitazoxanide in the Treatment of COVID-19: A paradigm for Antiviral Drugs Targeting Host-Infected Cells
Christian Bréchot, Jean François Rossignol
Medical Research Archives (2024) Vol. 12, Iss. 4
Open Access
Clinical Experience With Ivermectin and Nitazoxanide in the Management of COVID-19 Among Mexican Out- and Inpatients
Jorge García-Méndez, Luis E. Fernández-Garza, Karen Vallejo-Oviedo, et al.
Cureus (2024)
Open Access
Nitazoxanide Inhibits the Bifunctional Enzyme GlG6PD::6PGL of Giardia lamblia: Biochemical and In Silico Characterization of a New Druggable Target
Víctor Martínez‐Rosas, Beatriz Hernández‐Ochoa, Laura Morales-Luna, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11516-11516
Open Access
Page 1

Scroll to top